Amy Carter
Family Medicine · New Castle, INNPI 1821179235
Payments from drug & device makers
Across 62 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$251
- Pfizer$117
- Lundbeck LLC$94
- Novo Nordisk$56
- Lilly USA, LLC$52
- Novartis$48
- plus $413 from 18 others
What the payments were for
- Food & beverage$1,031100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $251 |
| Pfizer | 6 | $117 |
| Lundbeck LLC | 5 | $94 |
| Novo Nordisk | 4 | $56 |
| Lilly USA, LLC | 4 | $52 |
| Novartis | 3 | $48 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Medtronic | 3 | $44 |
| Johnson & Johnson | 3 | $38 |
| Tactile Systems Technology Inc | 2 | $29 |
| GSK | 2 | $27 |
| AstraZeneca | 2 | $25 |
| Merck | 1 | $21 |
| Abbott | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Amgen | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Romark Laboratories, LC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Mayne Pharma Commercial LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
How this compares
$1,031 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 642 | $222,156 |
| JardianceEmpagliflozin | 162 | $106,405 |
| TrulicityDulaglutide | 83 | $91,593 |
| XifaxanRifaximin | 24 | $61,522 |
| JanuviaSitagliptin Phosphate | 53 | $46,220 |
| MounjaroTirzepatide | 36 | $40,177 |
| CreonLipase/Protease/Amylase | 16 | $39,143 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 134 | $35,692 |
| EntrestoSacubitril/Valsartan | 49 | $32,227 |
| OzempicSemaglutide | 25 | $25,532 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $20,252 |
| InvokanaCanagliflozin | 22 | $19,871 |
| RexultiBrexpiprazole | 22 | $18,069 |
| TradjentaLinagliptin | 39 | $16,843 |
| MyrbetriqMirabegron | 39 | $16,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $117 | $233,492678 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $52 | $131,770119 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta | $27 | $57,560136 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Lokelma | $25 | $46,794103 claims |
| MerckJanuvia | $21 | $46,22053 claims |
| AbbVieCreon | $251 | $39,14316 claims |
| Johnson & JohnsonInvokana, Xarelto | $38 | $35,37458 claims |
| NovartisEntresto | $48 | $32,22749 claims |
| Novo NordiskOzempic | $56 | $25,53225 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $19 | $18,06922 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $16,65439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in New Castle
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.